IMMUNOHISTOCHEMISTRY PANEL (5-IHC) at Test Zone Diagnostic Center

IMMUNOHISTOCHEMISTRY PANEL (5-IHC) at Test Zone Diagnostic Center

Immunohistochemistry (IHC) represents a revolutionary advancement in diagnostic pathology, bridging the gap between traditional microscopic anatomy and molecular biology. The IMMUNOHISTOCHEMISTRY PANEL (5-IHC) at Test Zone Diagnostic Center is a highly specialized, state-of-the-art laboratory evaluation designed to identify specific protein antigens within tissue specimens. By utilizing a panel of five carefully selected monoclonal or polyclonal antibodies, this diagnostic procedure allows our consultant pathologists to visualize the precise localization, distribution, and expression levels of target proteins under a light microscope. This test is typically performed on formalin-fixed, paraffin-embedded (FFPE) tissue sections obtained from a previous biopsy or surgical resection. The clinical importance of a five-antibody panel cannot be overstated, particularly in the field of oncology. When standard hematoxylin and eosin (H&E) staining reveals an undifferentiated or poorly differentiated tumor, it is often impossible to determine the cell of origin based on cellular morphology alone. The 5-IHC panel provides the molecular resolution required to classify the malignancy with high precision, distinguishing between carcinomas, sarcomas, lymphomas, and melanomas. Furthermore, this panel plays a critical role in determining prognosis, predicting therapeutic response, and identifying candidates for targeted molecular therapies, such as hormone receptor-positive breast cancers or HER2-amplified gastric malignancies. At Test Zone Diagnostic Center in Lahore, Pakistan, we combine advanced automated staining technology with the expertise of highly qualified pathologists to deliver exceptionally accurate, reliable, and clinically actionable diagnostic reports that empower oncologists to design personalized, evidence-based treatment strategies for every patient.

Clinical Procedure: What to Expect

Patient Preparation

Because the IMMUNOHISTOCHEMISTRY PANEL (5-IHC) is an advanced laboratory analysis performed on tissue samples that have already been extracted from the patient, there is no direct physical preparation required for the patient on the day of the test. However, to ensure the highest diagnostic accuracy, patients and referring clinicians should observe the following guidelines:

• Submit Original Materials: Provide the original formalin-fixed, paraffin-embedded (FFPE) tissue blocks and corresponding hematoxylin and eosin (H&E) stained slides from the initial biopsy or surgical procedure.
• Provide Clinical History: Submit a detailed clinical summary, including the patient’s age, gender, primary symptoms, imaging findings (such as CT, MRI, or ultrasound reports), and suspected clinical diagnosis.
• Include Previous Pathology Reports: Always include copies of all previous histopathology and cytology reports related to the current illness.
• Ensure Proper Sample Transport: If transporting tissue blocks or slides from another facility to Test Zone Diagnostic Center, use a secure, temperature-controlled container to protect the specimens from extreme heat or physical damage, which can degrade protein antigens.
• No Fasting Required: Since no direct blood draw or invasive procedure is performed on the patient during this laboratory phase, fasting or medication adjustments are completely unnecessary.

During the Procedure

The laboratory workflow for the IMMUNOHISTOCHEMISTRY PANEL (5-IHC) at Test Zone Diagnostic Center is a highly standardized, multi-step process conducted by experienced histotechnologists and overseen by consultant pathologists:

• Tissue Sectioning: Ultra-thin sections, measuring approximately 3 to 4 micrometers, are cut from the paraffin block using a high-precision microtome and mounted onto specialized, positively charged glass slides to ensure firm tissue adhesion.
• Deparaffinization and Rehydration: The slides are heated and treated with xylene to remove the paraffin wax, followed by rehydration through a series of descending grades of alcohol and distilled water.
• Antigen Retrieval: To reverse the protein cross-linking caused by formalin fixation, the slides undergo Heat-Induced Epitope Retrieval (HIER) using a specialized microwave, pressure cooker, or water bath, exposing the target epitopes for antibody binding.
• Primary Antibody Incubation: The tissue sections are incubated with five distinct, highly specific primary antibodies. Each antibody is selected based on the clinical indication to target a specific cellular antigen.
• Secondary Detection System: After washing away unbound primary antibodies, a secondary antibody conjugated with an enzyme (such as horseradish peroxidase) is applied, which binds specifically to the primary antibodies.
• Chromogen Visualization: A chromogenic substrate, typically diaminobenzidine (DAB), is added. The enzyme reacts with the substrate to produce a visible, insoluble brown precipitate at the exact site of the target antigen.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to highlight cellular nuclei in blue, dehydrated, cleared, and sealed with a coverslip for microscopic evaluation.
• Pathological Interpretation: A consultant pathologist examines the stained slides under a high-resolution light microscope, assessing the percentage of positive cells, staining intensity, and subcellular localization (nuclear, cytoplasmic, or membranous) for each of the five markers.

When is an IMMUNOHISTOCHEMISTRY PANEL (5-IHC) Performed?

Subtyping Undifferentiated Malignancies

When a biopsy specimen consists of highly pleomorphic, poorly differentiated cells, standard microscopic examination is often insufficient to determine the tumor’s lineage. Clinicians request a 5-IHC panel containing lineage-specific markers (such as cytokeratins for epithelial cells, vimentin for mesenchymal cells, and CD45 for hematolymphoid cells) to accurately classify the tumor as a carcinoma, sarcoma, lymphoma, or melanoma, which is the critical first step in determining the correct therapeutic protocol.

Breast Cancer Receptor Profiling

In patients diagnosed with breast carcinoma, a specific 5-IHC panel is routinely performed to evaluate the expression of Estrogen Receptors (ER), Progesterone Receptors (PR), Human Epidermal Growth Factor Receptor 2 (HER2), Ki-67 (a marker of cellular proliferation), and a basal marker like Cytokeratin 5/6. This molecular profiling is essential for classifying the breast cancer subtype, predicting prognosis, and determining eligibility for endocrine therapies, targeted anti-HER2 agents, or specific chemotherapy regimens.

Identifying the Primary Site of Metastatic Tumors

Patients frequently present with metastatic disease in organs such as the liver, lungs, brain, or bones, without any obvious primary tumor site. Pathologists utilize a customized 5-IHC panel containing organ-specific transcription factors and cytokeratins (such as TTF-1 for lung/thyroid, CDX2 for gastrointestinal tract, GATA3 for breast/urothelium, and PSA for prostate) to trace the metastatic cells back to their primary site of origin, enabling oncologists to initiate highly targeted, organ-specific systemic therapies.

Lymphoma Classification and Characterization

Hematological malignancies represent an incredibly diverse group of diseases that require precise immunophenotyping for accurate classification. A 5-IHC panel targeting key lymphoid markers—such as CD3 (T-cells), CD20 (B-cells), CD30, CD15, and Cyclin D1—is performed to rapidly differentiate between Hodgkin and non-Hodgkin lymphomas, identify specific B-cell or T-cell lineages, and detect highly aggressive subtypes like Mantle Cell Lymphoma.

Determining Prognosis and Targeted Therapy Eligibility

Beyond basic diagnosis, understanding the biological aggressiveness of a tumor is vital for clinical staging and treatment planning. By incorporating markers such as Ki-67 (to measure the tumor’s active growth fraction) and p53 (to assess tumor suppressor gene mutations) alongside therapeutic targets like HER2 or PD-L1 into a 5-IHC panel, physicians can estimate tumor doubling time, predict metastatic potential, and identify patients who will benefit most from advanced immunotherapy or targeted molecular agents.

What Does an IMMUNOHISTOCHEMISTRY PANEL (5-IHC) Detect?

The IMMUNOHISTOCHEMISTRY PANEL (5-IHC) is designed to detect a wide array of clinically significant cellular antigens, proteins, and molecular markers. Depending on the specific panel selected by the pathologist, the test can detect:

• Cytokeratin (CK) AE1/AE3: Confirms epithelial differentiation, indicating a carcinoma.
• Vimentin: Detects mesenchymal cells, indicating a sarcoma.
• CD45 (Leukocyte Common Antigen): Confirms hematolymphoid origin, diagnostic of lymphoma or leukemia.
• S100 Protein: Detects neuroectodermal and melanocytic cells, pointing toward melanoma or neural tumors.
• SOX10: A highly sensitive and specific marker for malignant melanoma and sustentacular cells.
• Estrogen Receptor (ER): Detects nuclear hormone receptor expression in breast and gynecological cancers.
• Progesterone Receptor (PR): Identifies functional progesterone pathways, crucial for breast cancer prognosis.
• HER2/neu Oncoprotein: Detects cell membrane overexpression, guiding targeted trastuzumab therapy.
• Ki-67 Proliferation Antigen: Measures the percentage of actively dividing tumor cells, indicating tumor aggressiveness.
• TTF-1 (Thyroid Transcription Factor-1): Detects primary lung adenocarcinoma or thyroid carcinoma.
• CDX2: A nuclear marker indicating primary colorectal adenocarcinoma.
• GATA3: Detects primary breast carcinoma or urothelial carcinoma.
• Synaptophysin: Confirms neuroendocrine differentiation in tumors.
• Chromogranin A: Detects secretory granules in neuroendocrine neoplasms.
• CD20: Identifies B-lymphocyte lineage in lymphoproliferative disorders.
• CD3: Identifies T-lymphocyte lineage in lymphomas.
• Cyclin D1: Detects nuclear overexpression, highly specific for Mantle Cell Lymphoma.
• CD15: Detects Hodgkin and Reed-Sternberg cells in Classical Hodgkin Lymphoma.
• CD30: An activation marker positive in Hodgkin lymphoma and anaplastic large cell lymphoma.
• PSA (Prostate-Specific Antigen): Confirms prostatic origin in metastatic adenocarcinomas.
• Desmin: Detects myogenic differentiation in skeletal or smooth muscle tumors.
• Calretinin: A positive marker for mesothelial cells, aiding in the diagnosis of mesothelioma.
• p63: Identifies myoepithelial cells in breast tissue and squamous differentiation in lung tumors.
• p40: A highly specific marker for squamous cell carcinoma.
• p53 Protein: Detects abnormal accumulation or complete loss of the tumor suppressor protein, indicating TP53 gene mutation.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we recognize that waiting for pathology results can be a stressful period for patients and their families. Because immunohistochemistry is a highly complex, multi-step laboratory technique requiring precise tissue processing, antigen retrieval, antibody incubation, and meticulous microscopic evaluation by our consultant pathologists, the turnaround time for an IMMUNOHISTOCHEMISTRY PANEL (5-IHC) is typically 3 to 5 working days. This timeframe ensures that every step of the quality control process is strictly adhered to, minimizing the risk of diagnostic errors. Once the report is finalized and signed off by our consultant pathologist, patients and their referring physicians are immediately notified. Reports can be accessed securely online through the Test Zone Diagnostic Center web portal, delivered directly via WhatsApp, or collected as a high-quality printed document from our main diagnostic center in Lahore, Pakistan.

IMMUNOHISTOCHEMISTRY PANEL (5-IHC) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Epithelial Markers (e.g., CK AE1/AE3)	Negative in non-epithelial tissues (e.g., muscle, lymphoid tissue)	Positive in epithelial tumors (carcinomas); confirms carcinoma lineage.
Hematolymphoid Markers (e.g., CD45)	Positive only in normal inflammatory and lymphoid cells	Strong, diffuse positivity in tumor cells, indicating lymphoma or leukemia.
Melanocytic Markers (e.g., S100, SOX10)	Negative in epithelial and lymphoid tissues	Diffuse positivity in malignant melanoma and Schwann cell tumors.
Neuroendocrine Markers (e.g., Synaptophysin)	Negative in non-neuroendocrine tissues	Positive in neuroendocrine tumors, carcinoid tumors, and small cell carcinoma.
Proliferation Index (Ki-67)	Low expression (typically less than 5%) in resting, non-dividing tissues	Elevated expression (e.g., 30% to 90%) indicating highly aggressive, rapidly dividing tumors.
Hormone Receptors (ER/PR)	Variable expression in normal breast and endometrial tissues	Strong nuclear positivity in breast cancer, indicating eligibility for endocrine therapy.
HER2 Oncoprotein	Normal cell membrane expression (scored as 0 or 1+)	Overexpression (scored as 3+) indicating HER2 gene amplification and eligibility for targeted therapy.
Tissue-Specific Markers (e.g., TTF-1, CDX2)	Negative in unrelated organs and tissues	Positive expression indicating primary origin (e.g., TTF-1 positive in lung; CDX2 positive in colon).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for IMMUNOHISTOCHEMISTRY PANEL (5-IHC)?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists and histotechnologists specializing in oncopathology.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate support throughout the diagnostic journey.
• Quality Diagnostic Services: We adhere to international laboratory standards and participate in rigorous external quality assurance programs.
• Professional Reporting: Our reports provide detailed, comprehensive descriptions of antibody staining patterns, intensity, and clinical correlations.
• Modern Diagnostic Approach: We utilize state-of-the-art automated immunohistochemistry staining platforms to ensure maximum precision and reproducibility.
• Comfortable Environment: Our facilities in Lahore are designed to provide a welcoming, clean, and stress-free experience for sample submission.
• Convenient Location: Strategically located in Lahore, Pakistan, offering easy accessibility for patients and hospitals across the region.
• Commitment to Accurate Diagnosis: We are dedicated to providing the critical molecular insights needed for effective, personalized treatment planning.